



Reducing Time to Trial Activation
Draft agenda as of Feb. 22, 2019 and subject to change

| Monday, April 1, 2019 | |
|------------------------------|---|
| 11:30 a.m. – 5 p.m. | Workshop Check-In and Registration |
| 1 – 1:15 p.m. | <p>Welcome and Overview <i>Andy Johns, University of North Carolina at Chapel Hill</i></p> <p>Delays in clinical trial activation have negative impacts on an individual study’s feasibility and can affect a site’s desirability in the eyes of a sponsor. Awareness and knowledge of best practices in place across the clinical research industry allow sites to assess workflows, resourcing, training and quality elements within their research program.</p> <p>During this workshop, participants will hear from organizations that have deployed novel approaches to addressing the many delays that cause slow trial activation. Participants will also have the opportunity to share experiences, ideas, and approaches used to streamline and strengthen study activation and administration processes.</p> |
| 1:15 – 2 p.m. | <p>Session 1: Clinical Trial Agreements, Strategies to Decreasing Negotiation Times</p> <p><i>Panelists: Andy Johns, University of North Carolina at Chapel Hill; Robin Sweet, Axiom Law; Debra Freedholm, Axiom Law; Liz Moore, University of North Carolina at Chapel Hill</i></p> <p>Representatives from Axiom Law and the University of North Carolina at Chapel Hill will describe their partnership in efforts to reduce the time of negotiations for clinical trial contracts. Discuss metrics used to track success. Describe challenges and strategies taken to overcome those challenges.</p> |
| 2 – 2:45 p.m. | <p>Session 2: Strategies from the Sponsor Perspective on Decreasing Clinical Trial Activation Times</p> <p><i>Panelists: Brent Borneman, Global Clinical Trial Operations, Merck; Ahmad Ashanti, Global Clinical Trial Operations, Merck.</i></p> <p>Representatives from Merck Global Clinical Trial Operations will describe their “Master Suite Campaign” and how this initiative is decreasing overtime to clinical trial activation.</p> |
| 2:45 – 3:30 p.m. | <p>Session 3: Strategies for Developing Clinical Trial Budgets</p> <p><i>Panelists: Selvin Ohene, Wake Forest Baptist Health; Christine Nelson, University of North Carolina at Chapel Hill; Philip J. Butera, Levine Cancer Institute</i></p> <p>Representatives from Levine Cancer Institute, University of North Carolina at Chapel Hill and Wake Forest Baptist Health will describe efforts to improve the budget development process for clinical trials. Comparing centralized versus department level budget development and negotiation.</p> |
| 3:30 – 3:45 p.m. | BREAK |



| | |
|------------------|--|
| 3:45 – 4:55 p.m. | <p>Session 4: Common Challenges Faced in Decreasing the Time to Trial Activation Panelists will share examples of that have positively impacted clinical trial timelines</p> <p><i>Facilitator: Andy Johns, University of North Carolina at Chapel Hill</i></p> <p><i>Panelists: Denise Snyder, Duke University; Robin Sweet, Axiom Law; Debra Freedholm, Axiom Law; Liz Moore, University of North Carolina at Chapel Hill Brent Borneman, Global Clinical Trial Operations, Merck; Ahmad Ashanti, Global Clinical Trial Operations, Merck. Selvin Ohene, Wake Forest Baptist Health; Christine Nelson, University of North Carolina at Chapel Hill; Philip J. Butera, Levine Cancer Institute</i></p> <p>Is an interactive panel discussion facilitated by Andy Johns from the University of North Carolina at Chapel Hill, workshop attendees will hear from panelists their efforts to promote change within their organizations in an effort to decrease times to trial activation. We will have representatives from Axiom Law, Duke University, Levine Cancer Institute, University of North Carolina at Chapel Hill and Wake Forest Baptist Health.</p> |
| 4:55 – 5 p.m. | <p>Workshop Conclusion</p> |